Now showing items 1-20 of 26

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-07)
      <h4>Background</h4>Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using ...
    • Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. 

      Hoyle, AP; Ali, A; James, ND; Cook, A; Parker, CC; de Bono, JS; Attard, G; Chowdhury, S; Cross, WR; Dearnaley, DP; Brawley, CD; Gilson, C; Ingleby, F; Gillessen, S; Aebersold, DM; Jones, RJ; Matheson, D; Millman, R; Mason, MD; Ritchie, AWS; Russell, M; Douis, H; Parmar, MKB; Sydes, MR; Clarke, NW; STAMPEDE Investigators
      <h4>Background</h4>Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      <h4>Background</h4>Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: ...
    • Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. 

      Mason, MD; Clarke, NW; James, ND; Dearnaley, DP; Spears, MR; Ritchie, AWS; Attard, G; Cross, W; Jones, RJ; Parker, CC; Russell, JM; Thalmann, GN; Schiavone, F; Cassoly, E; Matheson, D; Millman, R; Rentsch, CA; Barber, J; Gilson, C; Ibrahim, A; Logue, J; Lydon, A; Nikapota, AD; O'Sullivan, JM; Porfiri, E; Protheroe, A; Srihari, NN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-05)
      Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally ...
    • Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. 

      Clarke, NW; Ali, A; Ingleby, FC; Hoyle, A; Amos, CL; Attard, G; Brawley, CD; Calvert, J; Chowdhury, S; Cook, A; Cross, W; Dearnaley, DP; Douis, H; Gilbert, D; Gillessen, S; Jones, RJ; Langley, RE; MacNair, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Parker, CC; Ritchie, AWS; Rush, H; Russell, JM; Brown, J; Beesley, S; Birtle, A; Capaldi, L; Gale, J; Gibbs, S; Lydon, A; Nikapota, A; Omlin, A; O'Sullivan, JM; Parikh, O; Protheroe, A; Rudman, S; Srihari, NN; Simms, M; Tanguay, JS; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A; Sydes, MR; Parmar, MKB; James, ND (2019-12)
      <h4>Background</h4>STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
      <h4>Background</h4>Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits ...
    • Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. 

      Crespo, M; van Dalum, G; Ferraldeschi, R; Zafeiriou, Z; Sideris, S; Lorente, D; Bianchini, D; Rodrigues, DN; Riisnaes, R; Miranda, S; Figueiredo, I; Flohr, P; Nowakowska, K; de Bono, JS; Terstappen, LWMM; Attard, G (2015-03-31)
      <h4>Background</h4>Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells ...
    • Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. 

      Conteduca, V; Wetterskog, D; Sharabiani, MTA; Grande, E; Fernandez-Perez, MP; Jayaram, A; Salvi, S; Castellano, D; Romanel, A; Romanel, A; Lolli, C; Casadio, V; Gurioli, G; Amadori, D; Font, A; Vazquez-Estevez, S; González Del Alba, A; Mellado, B; Fernandez-Calvo, O; Méndez-Vidal, MJ; Climent, MA; Duran, I; Gallardo, E; Rodriguez, A; Santander, C; Sáez, MI; Puente, J; Gasi Tandefelt, D; Wingate, A; Dearnaley, D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group; Demichelis, F; De Giorgi, U; Gonzalez-Billalabeitia, E; Attard, G (2017-07)
      <h4>Background</h4>There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement ...
    • Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? 

      Carden, CP; Sarker, D; Postel-Vinay, S; Yap, TA; Attard, G; Banerji, U; Garrett, MD; Thomas, GV; Workman, P; Kaye, SB; de Bono, JS (2010-02)
      Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to ...
    • Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. 

      Lorente, D; Omlin, A; Zafeiriou, Z; Nava-Rodrigues, D; Pérez-López, R; Pezaro, C; Mehra, N; Sheridan, E; Figueiredo, I; Riisnaes, R; Miranda, S; Crespo, M; Flohr, P; Mateo, J; Altavilla, A; Ferraldeschi, R; Bianchini, D; Attard, G; Tunariu, N; de Bono, J (2016-12)
      <h4>Background</h4>The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized ...
    • Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

      James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)
      <h4>Importance</h4>The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well ...
    • Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. 

      Linch, M; Goh, G; Hiley, C; Shanmugabavan, Y; McGranahan, N; Rowan, A; Wong, YNS; King, H; Furness, A; Freeman, A; Linares, J; Akarca, A; Herrero, J; Rosenthal, R; Harder, N; Schmidt, G; Wilson, GA; Birkbak, NJ; Mitter, R; Dentro, S; Cathcart, P; Arya, M; Johnston, E; Scott, R; Hung, M; Emberton, M; Attard, G; Szallasi, Z; Punwani, S; Quezada, SA; Marafioti, T; Gerlinger, M; Ahmed, HU; Swanton, C (2017-10)
      <h4>Background</h4>Intratumoural heterogeneity (ITH) is well recognised in prostate cancer (PC), but its role in high-risk disease is uncertain. A prospective, single-arm, translational study using targeted multiregion ...
    • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 

      Gillessen, S; Omlin, A; Attard, G; de Bono, JS; Efstathiou, E; Fizazi, K; Halabi, S; Nelson, PS; Sartor, O; Smith, MR; Soule, HR; Akaza, H; Beer, TM; Beltran, H; Chinnaiyan, AM; Daugaard, G; Davis, ID; De Santis, M; Drake, CG; Eeles, RA; Fanti, S; Gleave, ME; Heidenreich, A; Hussain, M; James, ND; Lecouvet, FE; Logothetis, CJ; Mastris, K; Nilsson, S; Oh, WK; Olmos, D; Padhani, AR; Parker, C; Rubin, MA; Schalken, JA; Scher, HI; Sella, A; Shore, ND; Small, EJ; Sternberg, CN; Suzuki, H; Sweeney, CJ; Tannock, IF; Tombal, B (2019-12)
    • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. 

      Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; Bristow, R; Carver, B; Castellano, D; Chung, BH; Clarke, N; Daugaard, G; Davis, ID; de Bono, J; Borges Dos Reis, R; Drake, CG; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, F; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Higano, CS; James, N; Kantoff, P; Kellokumpu-Lehtinen, P-L; Khauli, RB; Kramer, G; Logothetis, C; Maluf, F; Morgans, AK; Morris, MJ; Mottet, N; Murthy, V; Oh, W; Ost, P; Padhani, AR; Parker, C; Pritchard, CC; Roach, M; Rubin, MA; Ryan, C; Saad, F; Sartor, O; Scher, H; Sella, A; Shore, N; Smith, M; Soule, H; Sternberg, CN; Suzuki, H; Sweeney, C; Sydes, MR; Tannock, I; Tombal, B; Valdagni, R; Wiegel, T; Omlin, A (2018-02)
      <h4>Background</h4>In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level ...
    • Management strategies for hormone-refractory prostate cancer. 

      Attard, G; De Bono, JS; Parker, C; Horwich, A (2006-01-01)
    • Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. 

      Massard, C; Mateo, J; Loriot, Y; Pezaro, C; Albiges, L; Mehra, N; Varga, A; Bianchini, D; Ryan, CJ; Petrylak, DP; Attard, G; Shen, L; Fizazi, K; de Bono, J (2017-01)
      <h4>Background</h4>Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II trial of cabazitaxel plus abiraterone to assess ...
    • Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. 

      McDaniel, AS; Ferraldeschi, R; Krupa, R; Landers, M; Graf, R; Louw, J; Jendrisak, A; Bales, N; Marrinucci, D; Zafeiriou, Z; Flohr, P; Sideris, S; Crespo, M; Figueiredo, I; Mateo, J; de Bono, JS; Dittamore, R; Tomlins, SA; Attard, G (2017-11)
      <h4>Objectives</h4>To use a non-biased assay for circulating tumour cells (CTCs) in patients with prostate cancer (PCa) in order to identify non-traditional CTC phenotypes potentially excluded by conventional detection ...
    • Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. 

      Pezaro, CJ; Omlin, A; Mastris, K; ANZUP Consumer Advisory Panel; Attard, G; Beer, TM; Chi, KN; Chowdhury, S; Davis, ID; Drake, CG; de Bono, JS; Efstathiou, E; Gravis, G; Higano, CS; Hussain, M; James, N; Logothetis, CJ; Morgans, A; Parker, C; Ryan, CJ; Saad, F; Sartor, O; Small, EJ; Sternberg, CN; Sweeney, CJ; Tannock, I; Tombal, B; Gillessen, S (2017-08)